Literature DB >> 12028408

Progression of fibrosis in untreated patients with hepatitis C virus infection.

L Martin Lagging1, Johan Westin, Elisabeth Svensson, Nibia Aires, Amar P Dhillon, Magnus Lindh, Rune Wejstål, Gunnar Norkrans.   

Abstract

BACKGROUND/
METHODS: In order to evaluate the progression of liver fibrosis associated with Hepatitis C virus (HCV) infection, two liver biopsy specimens obtained prior to antiviral therapy from 98 patients with HCV were scored and evaluated using statistical methods appropriate for ordered categorical data. RESULTS/
CONCLUSIONS: Greater progression of fibrosis was seen with increasing time between the biopsies. Likewise, the change in fibrosis score was significantly more pronounced in the 11 patients whose first biopsy was obtained within the first year after acquiring HCV. A multivariate logistic regression analysis of possible explanatory factors for the fibrosis outcome showed that interface hepatitis in both biopsies, the time interval between the biopsies, and age at first biopsy were associated with change in the fibrosis score. In addition we found that higher age at the time of infection was associated with development of cirrhosis, that moderate intake of alcohol was associated with fibrosis progression, and that an inflammatory response in the form of moderate interface hepatitis in the first biopsy was not necessarily associated with greater progression of fibrosis if the second biopsy showed mild interface hepatitis. However, having moderate interface hepatitis later in the course of infection as reflected by the second biopsy may be detrimental. If moderate interface hepatitis early in the course of the disease is followed by less interface hepatitis later there is less fibrosis; and if moderate interface hepatitis persists, there is more fibrosis eventually.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12028408     DOI: 10.1034/j.1600-0676.2002.01623.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  21 in total

1.  Computer-aided morphometry of liver inflammation in needle biopsies.

Authors:  N Dioguardi; B Franceschini; C Russo; F Grizzi
Journal:  World J Gastroenterol       Date:  2005-11-28       Impact factor: 5.742

2.  Digital analysis of hepatic sections in mice accurately quantitates triglycerides and selected properties of lipid droplets.

Authors:  Fengxia Ge; Harrison Lobdell; Shengli Zhou; Chunguang Hu; Paul D Berk
Journal:  Exp Biol Med (Maywood)       Date:  2010-10-13

3.  Sampling variability of computer-aided fractal-corrected measures of liver fibrosis in needle biopsy specimens.

Authors:  Fabio Grizzi; Carlo Russo; Barbara Franceschini; Mariagrazia Di Rocco; Valter Torri; Emanuela Morenghi; Luigi Rainiero Fassati; Nicola Dioguardi
Journal:  World J Gastroenterol       Date:  2006-12-21       Impact factor: 5.742

4.  Is autoimmune hepatitis a frequent finding among HCV patients with intense interface hepatitis?

Authors:  Rosilene G Badiani; Vitória Becker; Renata M Perez; Carla A L Matos; Lara B Lemos; Valéria P Lanzoni; Luis Eduardo C Andrade; Alessandra Dellavance; Antonio Eduardo B Silva; Maria Lucia G Ferraz
Journal:  World J Gastroenterol       Date:  2010-08-07       Impact factor: 5.742

5.  Comparison of serum hepatitis C virus RNA and core antigen concentrations and determination of whether levels are associated with liver histology or affected by specimen storage time.

Authors:  L Martin Lagging; Clementina E Garcia; Johan Westin; Rune Wejstål; Gunnar Norkrans; Amar P Dhillon; Magnus Lindh
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

6.  Influence of iron on the severity of hepatic fibrosis in patients with chronic hepatitis C.

Authors:  Tsung-Jung Lin; Li-Ying Liao; Shyr-Yi Lin; Chih-Lin Lin; Ting-An Chang
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

Review 7.  Can Broadly Neutralizing Monoclonal Antibodies Lead to a Hepatitis C Virus Vaccine?

Authors:  Valerie J Kinchen; Andrea L Cox; Justin R Bailey
Journal:  Trends Microbiol       Date:  2018-04-24       Impact factor: 17.079

8.  Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C.

Authors:  Jordi Colmenero; Ramón Bataller; Pau Sancho-Bru; Marlene Domínguez; Montserrat Moreno; Xavier Forns; Miquel Bruguera; Vicente Arroyo; David A Brenner; Pere Ginès
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-07-23       Impact factor: 4.052

9.  Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C.

Authors:  Marija Zeremski; Lydia M Petrovic; Luis Chiriboga; Queenie B Brown; Herman T Yee; Milan Kinkhabwala; Ira M Jacobson; Rositsa Dimova; Marianthi Markatou; Andrew H Talal
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

10.  Hepatic steatosis in hepatitis C virus genotype 3 infection: does it correlate with body mass index, fibrosis, and HCV risk factors?

Authors:  Pratima Sharma; Vijayan Balan; Jose Hernandez; Marianne Rosati; James Williams; Hector Rodriguez-Luna; Joan Schwartz; Edwyn Harrison; Monte Anderson; Thomas Byrne; Hugo E Vargas; David D Douglas; Jorge Rakela
Journal:  Dig Dis Sci       Date:  2004-01       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.